

Bibliografia

- 1) Position Paper della Società Italiana di Farmacologia : Farmaci Equivalenti Quaderni della SIF 2011, 25 : 4-12
- 2) Le Corre P.: Bioequivalence and generics of index drugs with narrow therapeutics margins Presse Med 2010, 39/2 : 169-176
- 3) Gagne JJ, Avorn J, Shrank WH, Schneeweiss S : Refilling and switching of antiepileptic drugs and seizure-related events Clin Pharmacol Ther 2010, 88/3 : 347-353
- 4) Hattingh HL, Maganlal S, King MA : The impact on community pharmacy of the changing generic medicine substitution landscape J Law Med 2010, 17/5 : 761-771
- 5) Ferner RE, Lenney W, Marriot JF : Controversy over generic substitution BJM 2010, 340 : c2548
- 6) Misra A : Are biosimilars really generics ? Expert Opin Biol Ther 2010, 10/4: 489-94
- 7) Johnston A : Challenges of therapeutic substitution of drugs for economics reasons: focus on CVD prevention. Curr Med Res Opin 2010, 26/4: 878-878
- 8) Atar D, Carmena R, Clemmensen P et al : Clinical review: impact of statin substitution policies on patient outcomes Ann Med 2009, 41/4 :242-256
- 9) Finch R: Generic Antibiotics, antibiotics resistance and drug licensing Lancet Infect Dis 2010, 10/11: 754
- 10) Hakonsen H, Eilertsen M, Borge H et al.: Generic substitution : additional challenge for adherence in hypertensive patients? Curr Res Med Opin 2009, 25/10 : 2515-2521.

Autore

Il dottor Mauro Marin, Medico di Medicina Generale a Pordenone, è esperto in problematiche medico legali nell'ambito delle cure primarie